Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georges Imbert

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Analytical Chemistry|November 16, 2005
Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasmaK Olaf Boernsen, Stephan Gatzek, Georges Imbert
Drug Discovery Today|March 1, 2022
Democratizing data at Novartis through clinical trial data accessGabriel S Eichler, Georges Imbert, Janice Branson, et al.
Epilepsia|May 13, 2015
Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationshipDorotheé Kasteleijn-Nolst Trenité, Christian Brandt, Thomas Mayer, et al.
The Lancet. Neurology|June 9, 2012
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human studyBengt Winblad, Niels Andreasen, Lennart Minthon, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Analytical Chemistry|November 16, 2005
Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasmaK Olaf Boernsen, Stephan Gatzek, Georges Imbert
Drug Discovery Today|March 1, 2022
Democratizing data at Novartis through clinical trial data accessGabriel S Eichler, Georges Imbert, Janice Branson, et al.
Epilepsia|May 13, 2015
Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationshipDorotheé Kasteleijn-Nolst Trenité, Christian Brandt, Thomas Mayer, et al.
The Lancet. Neurology|June 9, 2012
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human studyBengt Winblad, Niels Andreasen, Lennart Minthon, et al.
Pageof 1